
Shares of telehealth company Doximity
Raymond James upgrades to "strong buy" from "outperform" rating; PT at $65
Brokerage sees potential from AI monetization and possible shifts toward direct-to-consumer for healthcare providers, which could support above-market growth
Sees long-term growth visibility and durability continues to improve
11 of 21 brokerages rate the stock "buy" or higher, 10 "hold"; their median PT is $65 - data compiled by LSEG
As of last close, stock down ~13% YTD